
Astrocyte Research Inc. is an investment technology boutique founded in 2014, specializing in full stack solutions that provide actionable insights for ETF issuers, alternative data providers, and professional investors. The company leverages machine learning and domain expertise to analyze global market risks and correlations, offering platforms like Portformer for fund intelligence and Breakpoint for risk alerts. With a focus on efficiency and data validation, Astrocyte positions itself as a key player in the financial services industry, helping clients optimize their investment strategies and portfolio analytics.

Astrocyte Research Inc. is an investment technology boutique founded in 2014, specializing in full stack solutions that provide actionable insights for ETF issuers, alternative data providers, and professional investors. The company leverages machine learning and domain expertise to analyze global market risks and correlations, offering platforms like Portformer for fund intelligence and Breakpoint for risk alerts. With a focus on efficiency and data validation, Astrocyte positions itself as a key player in the financial services industry, helping clients optimize their investment strategies and portfolio analytics.
Sector: Biopharma / neurotherapeutics
Headquarters: Cambridge, Massachusetts, United States
Stage: Early-stage, privately held
Founders / Key people: William Korinek (Co‑Founder, CEO); James Lechleiter (Co‑Founder)
Recent financing signal: Series B / pre‑Series B announced Aug 18, 2023
Neurological injury and neurodegeneration (TBI, stroke, concussion)
Biotechnology / Pharmaceuticals
“Dreavent Capital listed as lead investor on Series B; additional angel and regional life‑science investors reported”